세계의 뇌전증 지속증 시장 보고서(2025년)
Status Epilepticus Global Market Report 2025
상품코드 : 1811036
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 뇌전증 지속증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 연평균 복합 성장률(CAGR) 5.7%로 확대되어 16억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간 동안 성장이 예상되는 요인으로는 외상성 뇌손상의 증례 수 증가, 세계 인구의 고령화, 즉효성 있는 치료에 대한 수요 증가, 원격신경학 서비스 확대, 상환제도 개선 등이 있습니다. 예측되는 시장 동향으로는 침습성이 낮은 진단 방법으로의 이행, 웨어러블 발작 모니터링 기술의 이용 확대, 발작 치료에서 디지털 의료 기록의 통합 확대, 진단에서 인공지능(AI)의 이용, 혁신적인 항발작약 개발 등을 들 수 있습니다.

신경질환 증가는 향후 뇌전증 지속증 시장의 확대를 촉진할 것으로 예측됩니다. 이 질병은 중추 신경계와 말초 신경계에 영향을 미치며 인지 장애와 운동 기능 장애와 같은 다양한 장애를 초래합니다. 세계 인구의 고령화에 따라 뇌의 가소성 저하, 신경 세포 활동의 장애, 산화 스트레스 증가에 의해 이러한 질환의 유병률이 증가합니다. 이러한 유병률 증가는 신경세포 기능을 불안정화시킴으로써 발작이 장기화할 위험을 높여줍니다. 예를 들어 영국의 공중보건기구인 국민보건서비스(NHS)가 2024년 7월에 보고한 바에 따르면 2024년 6월 30일 현재 48만 7,432명의 치매 환자가 있으며 2024년 5월 31일에 비해 3,155명 증가하고 있습니다. 이러한 신경학적 사례 증가는 진단 및 관리 전략의 개선의 필요성을 강조하고 시장 성장에 기여합니다.

뇌전증 지속증 시장의 주요 기업은 AI를 탑재한 진단 툴을 포함한 기술적으로 첨단 솔루션의 혁신에 주력하고 있으며, 발작을 보다 정확하게 검출하고 신경내과에서의 케어의 효율을 높이고 있습니다. 이러한 AI 구동 플랫폼은 실시간 뇌 활동 모니터링을 활용하여 발작을 신속하게 파악하고 특히 긴급 환경에서 신속한 임상 판단을 지원합니다. 예를 들어 미국에 본사를 둔 Ceribell Inc.는 2023년 10월 Ceribell의 EEG 시스템과 통합하여 발작 활동을 실시간으로 지속적으로 분석하는 새로운 소프트웨어인 ClarityPro AI를 발표했습니다. 이 혁신은 신경학적 고통을 가진 환자에게 적시 개입을 제공하고 치료 결과를 개선하기 위해 건강 관리 팀을 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Status epilepticus represents a medical emergency defined by a seizure that continues for more than five minutes or recurrent seizures where the individual does not regain full consciousness between episodes. If not treated swiftly, it can lead to permanent neurological damage or even be fatal.

There are two primary types of status epilepticus: convulsive status epilepticus and non-convulsive status epilepticus. Convulsive status epilepticus is a critical and extended seizure episode marked by ongoing or repeated convulsions, commonly involving rhythmic muscle movements and unconsciousness. Management includes the use of medications such as first-generation, second-generation, and third-generation drugs, as well as neuromodulation devices. Drugs administered for treatment include ganaxolone, diazepam, phenobarbital, phenytoin and fosphenytoin, valproate, among others. These treatments are distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The status epilepticus market research report is one of a series of new reports from The Business Research Company that provides status epilepticus market statistics, including the status epilepticus industry's global market size, regional shares, competitors with an status epilepticus market share, detailed status epilepticus market segments, market trends and opportunities, and any further data you may need to thrive in the status epilepticus industry. This status epilepticus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The status epilepticus market size has grown strongly in recent years. It will grow from $1.27 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The expansion seen in the historic period is largely due to a rise in epilepsy cases, heightened awareness of neurological emergencies, increased utilization of benzodiazepines, more admissions to intensive care units (ICUs), and an overall surge in healthcare expenditure.

The status epilepticus market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. Anticipated growth during the forecast period can be attributed to factors such as a growing number of traumatic brain injury cases, an aging global population, greater demand for fast-acting therapeutics, the expansion of tele-neurology services, and better reimbursement schemes. Forecasted market trends include a move toward less invasive diagnostic methods, growing use of wearable seizure monitoring technology, wider integration of digital health records in seizure care, use of artificial intelligence (AI) in diagnostics, and the development of innovative anti-seizure medications.

The rise in neurological disorders is anticipated to drive the expansion of the status epilepticus market in the future. These disorders affect the central and peripheral nervous systems, resulting in various impairments such as cognitive and motor dysfunctions. As the global population ages, the prevalence of such conditions increases due to reduced brain plasticity, impaired neuronal activity, and higher oxidative stress. This growing prevalence elevates the risk of prolonged seizures by destabilizing neuronal functions. For example, as reported in July 2024 by the National Health Service (NHS), a UK-based public health provider, there were 487,432 diagnosed dementia patients as of June 30, 2024 - an increase of 3,155 cases compared to May 31, 2024. This rise in neurological cases underscores the need for improved diagnostic and management strategies, contributing to the market's growth.

Leading firms in the status epilepticus market are concentrating on innovating technologically advanced solutions, including AI-powered diagnostic tools, to better detect seizures and enhance care efficiency in neurology. These AI-driven platforms utilize real-time brain activity monitoring to identify seizures quickly and assist in making faster clinical decisions, particularly in emergency settings. For instance, in October 2023, U.S.-based Ceribell Inc. introduced ClarityPro AI, a new software that integrates with Ceribell's EEG systems to continuously analyze seizure activity in real time. This innovation supports healthcare teams in providing timely intervention and improving treatment outcomes for patients in neurological distress.

In February 2025, Immedica Pharma AB, a pharmaceutical company based in Sweden, acquired Marinus Pharmaceuticals Inc. to bolster its central nervous system (CNS) product lineup. This strategic acquisition allowed Immedica to gain access to ganaxolone, an essential therapy used in treating rare seizure-related disorders such as CDKL5 deficiency and status epilepticus. Marinus Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company recognized for its work in developing ganaxolone to manage refractory status epilepticus.

Major players in the status epilepticus market are Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Eisai Co. Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, Mylan N.V., Lupin Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Neuraxpharm, Ligand Pharmaceuticals Incorporated, Rafa Laboratories Ltd., Aquestive Therapeutics, Nobelpharma Co. Ltd., Neurelis Inc., SAGE Therapeutics, Immedica Pharma AB, Sedor Pharmaceuticals, and Crossject SA.

North America was the largest region in the status epilepticus market in 2024. The regions covered in status epilepticus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the status epilepticus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The status epilepticus market consists of revenues earned by entities by providing services such as emergency medical interventions, critical care management, diagnostic imaging, and neurocritical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The status epilepticus market also includes sales of benzodiazepines, antiepileptic drugs, general anesthetics, infusion pumps, and emergency medical kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Status Epilepticus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on status epilepticus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for status epilepticus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The status epilepticus market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Status Epilepticus Market Characteristics

3. Status Epilepticus Market Trends And Strategies

4. Status Epilepticus Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Status Epilepticus Growth Analysis And Strategic Analysis Framework

6. Status Epilepticus Market Segmentation

7. Status Epilepticus Market Regional And Country Analysis

8. Asia-Pacific Status Epilepticus Market

9. China Status Epilepticus Market

10. India Status Epilepticus Market

11. Japan Status Epilepticus Market

12. Australia Status Epilepticus Market

13. Indonesia Status Epilepticus Market

14. South Korea Status Epilepticus Market

15. Western Europe Status Epilepticus Market

16. UK Status Epilepticus Market

17. Germany Status Epilepticus Market

18. France Status Epilepticus Market

19. Italy Status Epilepticus Market

20. Spain Status Epilepticus Market

21. Eastern Europe Status Epilepticus Market

22. Russia Status Epilepticus Market

23. North America Status Epilepticus Market

24. USA Status Epilepticus Market

25. Canada Status Epilepticus Market

26. South America Status Epilepticus Market

27. Brazil Status Epilepticus Market

28. Middle East Status Epilepticus Market

29. Africa Status Epilepticus Market

30. Status Epilepticus Market Competitive Landscape And Company Profiles

31. Status Epilepticus Market Other Major And Innovative Companies

32. Global Status Epilepticus Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Status Epilepticus Market

34. Recent Developments In The Status Epilepticus Market

35. Status Epilepticus Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기